Patients with cancer are at risk for potentially deadly toxicities from chemotherapy overtreatment if kidney function is not accurately estimated beforehand. New research suggested that the use of ...
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results